We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New BD Assay Speeds Discovery in Autoimmune Disorders, Immuno-Oncology, and Infectious Diseases

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: BD Rhapsody TCR/BCR multiomic assay advances immunology research capabilities in multiomics (Photo courtesy of BD)
Image: BD Rhapsody TCR/BCR multiomic assay advances immunology research capabilities in multiomics (Photo courtesy of BD)

Multiomics is a rapidly developing field where researchers look at multiple types of molecules on the same cell, which can provide greater biological insights than the traditional approach of analyzing molecules in aggregate, across many cells. Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has launched the BD Rhapsody TCR/BCR Multiomic Assay, an innovative set of reagents that enables researchers to more easily and comprehensively analyze important cells in the immune system, providing a tool to advance research in autoimmune disorders, immuno-oncology and infectious diseases.

The BD Rhapsody TCR/BCR Multiomic Assay supplies immunology researchers the specific reagents required to profile full-length T cell and B cell receptors, two of the most important cellular elements in the immune system, to better understand the adaptive immune response and enable applications such as evaluating cellular responses to new drugs. The BD Rhapsody TCR/BCR Multiomic Assay has a wide range of applications, including screening for antigen specific cells in response to infectious diseases, immune repertoire profiling of tumor infiltrating lymphocytes, and vaccine development and evaluation of efficacy. The assay is optimized to work with the company’s BD Rhapsody Single-Cell Analysis System workflow, which enables higher capture rates than currently available solutions, preserving fragile cells in the process. This first-generation kit is now available globally and is the latest addition to BD’s portfolio of tools for multiomic analysis.

“With the release of the BD Rhapsody TCR/BCR Multiomic Assay, we are reinforcing our commitment to the incredibly exciting field of multiomics and single-cell research and the delivery of robust, easy-to-use tools that offer researchers valuable and deep insights,” said Puneet Sarin, worldwide president at BD Biosciences. “Single-cell analysis tools like the BD Rhapsody TCR/BCR Multiomic Assay and BD Rhapsody Single-Cell Analysis System support our customers’ need for greater sensitivity and specificity studying cells of interest and drive rapid advancements in immunology, including research in therapeutic response and cell therapy.”

Related Links:
Becton, Dickinson and Company 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.